The role of molecular markers in predicting response to therapy in patients with colorectal cancer

Molecular Diagnosis and Therapy

Volumn 12, Issue 2, 2008, Pages 87-98

  Shankaran, Veena ^a   Wisinski, Kari B ^a   Mulcahy, Mary F ^a   Benson III, Al B ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Biomarkers; Colorectal cancer, treatment; Diagnostics

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MOLECULAR MARKER; OXALIPLATIN; PANITUMUMAB; RITUXIMAB; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CELL MEDIATED CYTOTOXICITY; CHROMOSOME 18Q; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DNA FINGERPRINTING; DRUG BINDING; DRUG FATALITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MOLECULAR INTERACTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

EID: 42449115370     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256274     Document Type: Review

References (80)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007 Jan-Feb; 57 (1): 43-66
2. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004; 54: 295-308
3. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004 Jun 3; 350 (23): 2343-51
4. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years [abstract]. J Clin Oncol 2007; 25 (18S Jun 20 Suppl.): 4007
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3; 350 (23): 2335-42
6. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004 Jan 15; 22 (2): 229-37
7. Baddi L, Benson 3rd AB. Adjuvant therapy in stage II colon cancer: current approaches. Oncologist 2005 May; 10 (5): 325-31
8. Douillard JY, Bennouna J. Adjuvant chemotherapy for colon cancer: a confusing area! Ann Oncol 2005 Dec; 16 (12): 1853-4
9. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990 Feb 8; 322 (6): 352-8
10. Nauta R, Stablein DM, Holyoke ED. Survival of patients with stage B2 colon carcinoma: the Gastrointestinal Tumor Study Group experience. Arch Surg 1989 Feb; 124 (2): 180-2
11. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9 (6): 606-16
12. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000 Jul; 124 (7): 979-94
13. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993 May 7; 260 (5109): 812-6
14. Peltomaki P, Aaltonen LA, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993 May 7; 260 (5109): 810-2
15. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993 May 7; 260 (5109): 816-9
16. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003 Mar 6; 348 (10): 919-32
17. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998 Nov 15; 58 (22): 5248-57
18. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007 Jul; 133 (1): 48-56
19. Kim H, Jen J, Vogelstein B, et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994 Jul; 145 (1): 148-56
20. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993 Jun 10; 363 (6429): 558-61
21. Bettstetter M, Dechant S, Ruemmele P, et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 2007 Jun 1; 13 (11): 3221-8
22. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000 Jan 13; 342 (2): 69-77
23. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001 Sep; 10 (9): 917-23
24. Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001 Aug; 1 (2): 104-9
25. Elsaleh H, Powell B, Soontrapornchai P, et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 2000; 58 (1): 52-9
26. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003 Jul 17; 349 (3): 247-57
27. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005 Jan 20; 23 (3): 609-18
28. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999 Jul; 117 (1): 123-31
29. Meyers M, Wagner MW, Hwang HS, et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001 Jul 1; 61 (13): 5193-201
30. Benson 3rd AB. Individualizing adjuvant therapy for stage II colon cancer: the potential role of MSI and 18q LOH. Colorectal Cancer Index Rev 2006; 7 (1): 4-7
31. Elsaleh H, Joseph D, Grieu F. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000 May 20; 355 (9217): 1745-50
32. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004 Feb; 126 (2): 394-401
33. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2007 Mar 1; 25 (7): 767-72
34. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998 Dec 17; 396 (6712): 643-9
35. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994 Jul 28; 331 (4): 213-21
36. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001 Apr 19; 344 (16): 1196-206
37. Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002 Nov 2; 360 (9343): 1381-91
38. Oxaliplatin, leucovorin, and fluorouracil with or without bevacizumab in treating patients who have undergone surgery for stage II colon cancer. ClinicalTrials.gov Identifier: NCT00217737 [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00217737 [Accessed 2008 Mar 25]
39. Biswas S, Chytil A, Washington K, et al. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 2004 Jul 15; 64 (14): 4687-92
40. Grady WM, Rajput A, Myeroff L, et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998 Jul 15; 58 (14): 3101-4
41. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995 Jun 2; 268 (5215): 1336-8
42. Johnston PG, Drake JC, Trepel J, et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992 Aug 15; 52 (16): 4306-12
43. Pasche B, Mulcahy M, Benson 3rd AB. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Pract Res 2002 Apr; 16 (2): 331-45
44. Grem JL, Danenberg KD, Behan K, et al. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's anticancer drug screen. Clin Cancer Res 2001 Apr; 7 (4): 999-1009
45. Allen WL, Johnston PG. Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005 Jul 10; 23 (20): 4545-52
46. Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994 Dec; 12 (12): 2640-7
47. Lenz HJ, Danenberg KD, Leichman CG, et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998 May; 4 (5): 1227-34
48. Yamachika T, Nakanishi H, Inada K, et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998 Jan 1; 82 (1): 70-7
49. Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002 Apr 1; 20 (7): 1721-8
50. Beck A, Etienne MC, Cheradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A (10): 1517-22
51. van Triest B, Pinedo HM, van Hensbergen Y, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999 Mar; 5 (3): 643-54
52. Paradiso A, Simone G, Petroni S, et al. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000 Feb; 82 (3): 560-7
53. Leichman L, Lenz HJ, Leichman CG, et al. Quantitation of intratumoral thymidy-late synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 1995 Jul-Aug; 31A (7-8): 1306-10
54. Corsi DC, Ciaparrone M, Zannoni G, et al. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer 2002 Mar; 38 (4): 527-34
55. Bevacizumab and oxaliplatin combined with irinotecan or leucovorin and fluorouracil in treating patients with metastatic or recurrent colorectal cancer. ClinicalTrials.gov Identifier: NCT00098787 [online]. Available from URL: http://clinicaltrials.gov/ct/show/NCT00098787 [Accessed 2008 Mar 25]
56. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000 Apr; 6 (4): 1322-7
57. Ciaparrone M, Quirino M, Schinzari G, et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 2006; 70 (5): 366-77
58. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998 May 6; 90 (9): 675-84
59. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001 Sep 1; 85 (5): 692-6
60. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 Jul 22; 351 (4): 337-45
61. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001 Sep 1; 92 (5): 1331-46
62. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993 Apr 15; 71 (8): 2454-60
63. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004 Apr 1; 22 (7): 1201-8
64. Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr) [abstract 3547]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl. Pt I)
65. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology 2007 [online]. Available from URL: http://www.nccn.org/ professionals/physician_gls/PDF/colon.pdf [Accessed 2008 Mar 25]
66. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007 Aug 1; 25 (22): 3238-45
67. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005 May; 6 (5): 279-86
68. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006 Oct 20; 24 (30): 4914-21
69. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007 Aug 1; 25 (22): 3230-7
70. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Lievre J Clin Oncol 2008 Jan 20; 26 (3): 364-79
71. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007 Apr 23; 96 (8): 1166-9
72. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008 Mar; 19 (3): 508-15
73. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003 Nov 1; 21 (21): 3940-7
74. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007 Aug 20; 25 (24): 3712-8
75. Johnston PG, Mulligan K, Kay E, et al. A genetic signature of relapse in stage II colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) using a unique disease specific colorectal array [abstract no. 3519]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl. Pt I)
76. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005 May 20; 23 (15): 3526-35
77. Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003 Dec 15; 63 (24): 8791-812
78. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004 May 1; 22 (9): 1564-71
79. O'Connell MJ, Paik S, Yothers G, et al. Relationship between tumor gene expression and recurrence in stage II/III colon cancer: quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue [abstract no. 3518]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl. Pt I)
80. Mariadason JM, Augenlicht LH, Arango D. Microarray analysis in the clinical management of cancer. Hematol Oncol Clin North Am 2003 Apr; 17 (2): 377-87